Vyne Therapeutics Inc
NASDAQ:VYNE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Aarey Drugs and Pharmaceuticals Ltd
NSE:AAREYDRUGS
|
IN |
Vyne Therapeutics Inc
Revenue
Vyne Therapeutics Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Vyne Therapeutics Inc
NASDAQ:VYNE
|
Revenue
$570k
|
CAGR 3-Years
6%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$96.4B
|
CAGR 3-Years
8%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$291.6m
|
CAGR 3-Years
-82%
|
CAGR 5-Years
-63%
|
CAGR 10-Years
-33%
|
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$62.6B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
8%
|
CAGR 10-Years
3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$65.8B
|
CAGR 3-Years
4%
|
CAGR 5-Years
9%
|
CAGR 10-Years
5%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$72.2B
|
CAGR 3-Years
38%
|
CAGR 5-Years
23%
|
CAGR 10-Years
14%
|
|
Vyne Therapeutics Inc
Glance View
VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. The company is headquartered in Bridgewater, New Jersey and currently employs 28 full-time employees. The company went IPO on 2018-01-25. The firm is engaged in developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions and rare skin diseases with high unmet medical need. The Company’s proprietary pipeline FMX114, which is a potential treatment of mild-to-moderate atopic dermatitis in patients 12 years of age and older, and access to a library of bromodomain and extra-terminal (BET) domain inhibitors in both topical and oral forms for the potential treatment of major immuno-inflammatory conditions and rare skin diseases.
See Also
What is Vyne Therapeutics Inc's Revenue?
Revenue
570k
USD
Based on the financial report for Dec 31, 2025, Vyne Therapeutics Inc's Revenue amounts to 570k USD.
What is Vyne Therapeutics Inc's Revenue growth rate?
Revenue CAGR 5Y
-51%
Over the last year, the Revenue growth was 14%. The average annual Revenue growth rates for Vyne Therapeutics Inc have been 6% over the past three years , -51% over the past five years .
